Company / SG&A Expense
Arcellx, Inc. SG&A Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$117.8M
FY2025
5-year range
$18.1M / $117.8M
FY2021-FY2025
Trend
+33.2%
vs FY2024
Sector context
#104 of 213
Health Care
What the data says
At $118M, Arcellx, Inc.'s sg&a expense ranks #110 of 213 in the Health Care sector. SG&A Expense has increased for 4 consecutive years, from $18M in FY2021 to $118M in FY2025.
Based on SEC 10-K filings.
$118M in FY2025 with a 3-year CAGR of +41.3%.
Increased from $66M to $118M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +41.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#110 of 213 in Health CareTop 51% of 213This company $117.8M Sector average $722.3M
▼
-83.7% below sector average
Key checks
Key Insights
- Arcellx, Inc.'s sg&a expense has grown for 4 consecutive years.
- 3-year CAGR of +41.3%, indicating consistent growth.
- In FY2025, sg&a expense increased 33.2% year-over-year.
- Ranks #104 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.02 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $117.8M | +33.2% |
| FY2024 | $88.4M | +33.3% |
| FY2023 | $66.3M | +59.1% |
| FY2022 | $41.7M | +130.0% |
| FY2021 | $18.1M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026